Skip to Main Content

Paper Details

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
bioRxiv
0
2023
AR, Androgen, Androgen Receptor, Androgen receptor, CUT, HOX, NE splicing factor, OC2, ONECUT2, PC, Prostate Cancer, adenocarcinoma, androgen, chromatin, enzalutamide, glucocorticoid receptor, glucuronidation genes, prostate cancer, stem, super-enhancers
Author NameAffiliation
Stephen J FreedlandSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Colm MorrisseyUniversity of Washington
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center
Elahe A MostaghelEducation and Clinical Center (GRECC)
Isla P GarrawayDavid Geffen School of Medicine at university of california los angeles, 10833 Le Conte Ave 66-188 CHS university of california los angeles
Sungyong YouSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Michael R FreemanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
  • 1 - 8

Datasets

Release 1.2